Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
crystal710 / Pixabay

Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia

According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…

Continue Reading Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
jarmoluk / Pixabay

Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released

According to a story from BioPortfolio, the global biopharmaceutical company Celgene Corporation recently announced the release of early data from the dose-escalation portion of a Phase 1/2 clinical trial of lisocabtagene…

Continue Reading Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients
https://pixabay.com/en/earth-planet-space-satellite-1913747/

International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients

Chronic myelomonocytic leukemia, or CMML, is a rare condition. However, it has similarities to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). That being said, it still a unique diagnosis, and…

Continue Reading International Experts Met with Goal to Improve Care for Chronic Myelomonocytic Leukemia Patients
Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation
Source: Pixabay.com

Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation

Huntington's Disease is a neurodegenerative condition caused by a genetic mutation. It results in progressive decline of motor skills. It also affects cognitive function. Patients experience decline for 15-20 years…

Continue Reading Potential New Treatment for Huntington’s Disease Granted Orphan Drug Designation
A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Source: Pixabay.com

A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Mantle cell lymphoma is caused by a genetic mutation which  produces cancerous white blood cells. Of course, these are the cells which fight infection in a normal body. Therefore in…

Continue Reading A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Experimental Gene Therapy for Fanconi Anemia Earns Fast Track and Regenerative Medicine Advanced Therapy Designation

According to a story from BioPortfolio, the gene therapy company Rocket Pharmaceuticals has recently announced that the company's investigational gene therapy RP-L102 has earned both Fast Track and Regenerative Medicine…

Continue Reading Experimental Gene Therapy for Fanconi Anemia Earns Fast Track and Regenerative Medicine Advanced Therapy Designation
New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
https://patientworthy.com/wp-content/uploads/2018/11/perspective-175642_1280.png

New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!

Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune disorder. It's a rare condition characterized by muscle weakness in the limbs. When the muscle weakness includes the respiratory muscles, the disease can…

Continue Reading New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
kfuhlert / Pixabay

New Approval Gives Juvenile Idiopathic Arthritis Patients More Options

On November 26, 2018, the FDA approved a new autoinjector for individuals with severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular or systemic juvenile idiopathic arthritis (aged 2 and older). It's…

Continue Reading New Approval Gives Juvenile Idiopathic Arthritis Patients More Options